

## Product Information

### MISSION® shRNA Control Transduction Particles

Catalog Numbers **SHC001V, SHC002V, SHC003V, SHC004V, SHC005V, SHC007V, SHC008V, SHC009V, SHC010V, SHC011V, SHC012V, SHC013V, SHC014V, SHC015V, SHC016V, SHC201V, SHC202V, SHC203V, SHC204V, SHC216V, SHC312V, SHC314V, SHC317V, SHC332V, SHC334V, SHC337V, SHC001H, SHC002H, SHC003H, SHC004H, and SHC016H**

Storage Temperature –70 °C

## TECHNICAL BULLETIN

### Product Description

RNA interference (RNAi) is a powerful gene-specific silencing mechanism in mammalian cells. The MISSION® product line is a viral vector-based RNAi library against annotated mouse and human genes. shRNAs that are processed into siRNAs intracellularly are expressed from amphotropic lentivirus particles, allowing screening in a wide range of mammalian cell types. In these cells, MISSION shRNA clones permit rapid, cost efficient loss-of-function and genetic interaction screens.

Unlike murine-based MMLV or MSCV retroviral systems, lentiviral-based particles permit efficient infection and integration of the specific shRNA construct into differentiated and non-dividing cells, such as neurons and dendritic cells,<sup>1</sup> overcoming low transfection and integration difficulties associated with these cell lines. Self-inactivating replication incompetent viral particles are produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids.<sup>2,3</sup> In addition, the lentiviral transduction particles are pseudotyped with an envelope G glycoprotein from Vesicular Stomatitis Virus (VSV-G), allowing transduction of a wide variety of mammalian cells.<sup>4</sup>

Figure 1 depicts the base vector for all TRC1 and TRC1.5 clones (pLKO.1-puro). Figure 2 depicts the base vector for all TRC2 clones (TRC2-pLKO-puro). The TRC2 vector has a single additional element in comparison to the TRC1 vector. This element is the WPRE,<sup>5</sup> or the Woodchuck Hepatitis Post-Transcriptional Regulatory Element. WPRE allows for enhanced expression of transgenes delivered by lentiviral vectors.<sup>6</sup>

When conducting experiments using MISSION shRNA lentiviral particles, proper controls are a key element of experimental design to permit accurate interpretation of knockdown results and provide assurance of the specificity of the response observed. The MISSION shRNA Control Transduction Particles are lentiviral transduction particles that are useful as both positive and negative controls in experiments using the MISSION shRNA library.

Sigma's recommended controls for any shRNA experiment are provided in the **Control Selection Table** and are closely aligned with the controls suggested in the *Nature Cell Biology* editorial.<sup>7</sup> Please consult the Control Selection Table to select the controls that are most appropriate for your shRNA experiments. The **Quick Reference Guide** provides relevant insert sequence and gene target information specific to each product.

### TRC1/TRC1.5 Controls

The TRC1 and TRC1.5 pLKO.1-puro Empty Vector Control Transduction Particles (SHC001V and SHC001H) do not contain a hairpin insert and provide a useful negative control that will not activate the RNA-induced silencing complex or RISC.

The TRC1 and TRC1.5 pLKO.1-puro Non-Mammalian shRNA Control Transduction Particles (SHC002V and SHC002H) are negative controls containing a sequence that should not target any known mammalian genes, but will engage with RISC. This control may cause some knockdown of tGFP, which should be taken into consideration when working with tGFP expressing cell lines.

The TRC1 and TRC1.5 pLKO.1-puro Non-Target shRNA Control Transduction Particles (SHC016V and SHC016H) target no known genes from any species. These non-mammalian and non-target controls serve as useful references for interpretation of knockdown results.

The TRC1 and TRC1.5 pLKO.1-puro-CMV-TurboGFP™ Positive Control Transduction Particles (SHC003V and SHC003H) contain a gene encoding TurboGFP driven by the CMV (cytomegalovirus) promoter and can be useful positive controls for measuring transduction efficiency and optimizing shRNA delivery. Alternative fluorophore choices are available in the TRC1 and TRC1.5 pLKO.1-puro vector backbone. These fluorophores are also driven by the CMV promoter, and include TagCFP™ (SHC010V), TagYFP™ (SHC011V), TagRFP™ (SHC012V), and TagFP635™ (SHC013V).

Silencing of the CMV promoter may be a problem in some cell types.<sup>8</sup> For these cells, the Ubiquitin C promoter (UbC) can be a viable alternative.<sup>9</sup> Alternate promoter choices are available in the TRC1 and TRC1.5 pLKO.1-puro vector backbone. The UbC-TurboGFP (SHC014V) and UbC-TagFP635 (SHC015V) controls were generated for these types of applications. Please refer to Figure 3 for corresponding excitation and emission wavelengths.

The transduction particles containing shRNAs designed against commonly used reporter genes, TurboGFP (SHC004V and SHC004H), eGFP (SHC005V), and Luciferase (SHC007V), are useful as positive controls for knockdown and can be particularly applicable when working with stably expressing reporter cell lines. Because these shRNAs do not target any known human or mouse genes, they can also be used as non-targeting controls in many shRNA experiments.

$\beta_2$ -microglobulin is a MHC Class I molecule present on most cell types.<sup>10</sup> It is commonly used as an endogenous control due to this universal expression. The MISSION pLKO.1-puro B2M shRNA Control Transduction Particles (SHC008V) specifically targets the human  $\beta_2$ -microglobulin gene and reduces expression by ~80% in A549 cells via quantitative RT-PCR analysis.

Rho GDP dissociation inhibitor (GDI) alpha (ARHGDIA) is an ubiquitously expressed protein that acts on Rho GTPases, including RhoA, Rac1, and Cdc42, by keeping these proteins in an inactive state.<sup>11,12</sup> Complete understanding of ARHGDIA's roles is still being elucidated but it is believed to be involved in various signal transduction pathways and cellular cytoskeleton functions. The MISSION pLKO.1-puro ARHGDIA shRNA Control Transduction Particles (SHC009V), specifically targets the human ARHGDIA gene and reduces expression by 90% or more in A549 cells, as verified by both quantitative RT-PCR and Western blot analysis using Anti-Rho-GDI, Catalog Number R3025.

The selected clones for both human positive controls were identified from the existing and available target sets for these genes because they have provided consistent knockdown, which can be useful in experimental optimization.

High titer controls SHC001H, SHC002H, SHC003H, SHC004H, and SHC016H at titers of at least  $10^9$  transducing units per ml (TU/ml) are designed for experiments where cell cultures require high MOI or where low volume is needed.

#### TRC2 Controls

The TRC2 pLKO.5-puro Empty Vector Control Transduction Particles (SHC201V) does not contain a hairpin insert and is a useful negative control that will not activate the RNA-induced silencing complex or RISC.

The TRC2 pLKO.5-puro Non-Mammalian shRNA Control Transduction Particles (SHC202V) is a negative control containing a sequence that should not target any known human or mouse gene, but will engage with RISC. This non-targeting control serves as a useful reference for interpretation of knockdown results.

The TRC2 pLKO.5-puro-CMV-TurboGFP™ Positive Control Transduction Particles (SHC203V) contains a gene encoding TurboGFP driven by the CMV promoter and can be a useful positive control for measuring transduction efficiency and optimizing shRNA delivery.

Also available are the transduction particles containing shRNA to TurboGFP (SHC204V). This control is useful as a positive control for knockdown and can be particularly applicable when working with stably expressing reporter cell lines. Because this vector does not target any known human or mouse genes, it can also be used as non-targeting controls in many shRNA experiments.

#### Inducible Controls

Sigma offers IPTG-inducible shRNA vectors. The pLKO vector has been redesigned to contain a LacI (repressor) and a modified human U6 shRNA promoter with LacO (operator) sequences. In the absence of IPTG (isopropyl  $\beta$ -D-1-thiogalactoside), an analogue of lactose, LacI binds to LacO preventing expression of the shRNA. When IPTG is present, the allosteric LacI repressor changes conformation, releasing itself from lacO modified human U6 promoter, and subsequently allows expression of the shRNA.

We are proud to offer two different IPTG inducible vectors for your research. The preferred inducible vector, pLKO\_IPTG\_3xLacO, contains three lac operon sequences (two in the U6 promoter and one 3' of the promoter) affording both tight regulation and great gene silencing. Whereas, the pLKO\_IPTG\_1xLacO vector contains a single lac operon sequence in the U6 promoter, which allows for an advantage to shRNA expression, but looser control of the promoter when not induced.

The 1X and 3X LacO Inducible Non-Target shRNA Control Transduction Particles (SHC312V and SHC332V), are negative controls containing a sequence that should not target any genes in any known species, but will engage with RISC.

The 1X and 3X LacO Inducible shRNA vectors designed against commonly used reporter genes: TurboGFP (SHC314V and SHC334V) and Luciferase (SHC317V and SHC337V) are useful as positive controls for knockdown and can be particularly applicable when working with stably expressing reporter cell lines. Because these vectors do not target any known human or mouse genes, they can also be used as non-targeting controls in many shRNA experiments.

#### **Reagents**

All controls are supplied in Dulbecco's Modified Eagle's Medium with 10% heat-inactivated fetal bovine serum and penicillin-streptomycin.

SHC001V, SHC002V, SHC003V, SHC004V, SHC005V, SHC007V, SHC008V, SHC009V, SHC010V, SHC011V, SHC012V, SHC013V, SHC014V, SHC015V, SHC201V, SHC202V, SHC203V, and SHC204V are provided as a 200  $\mu$ L frozen stock containing at least  $10^6$  TU/ml.

SHC001H, SHC002H, SHC003H, SHC004H, and SHC016V are provided as a 200  $\mu$ L frozen stock containing at least  $10^9$  TU/mL.

The MISSION Control Transduction Particles are titered via a p24 antigen ELISA assay and pg/mL of p24 are then converted to TU/ml using a conversion factor. The conversion can be viewed at:

[http://www.sigmaaldrich.com/life-science/functional-genomics-and-rnai/shrna/learning-center/mission-faqs/lentiviral-faqs.html#p24\\_assay](http://www.sigmaaldrich.com/life-science/functional-genomics-and-rnai/shrna/learning-center/mission-faqs/lentiviral-faqs.html#p24_assay).

#### **Materials suggested but not provided**

- Mammalian cells to be transduced
- Minimum Essential Medium containing 10% fetal calf serum or growth medium optimized for the specific cell line
- 96-well cell culture treated plates
- Puromycin dihydrochloride, cell culture tested, Catalog Number P8833
- Hexadimethrine bromide, Catalog Number H9268
- Anti-Rho-GDI, Catalog Number R3025

#### **Precautions and Disclaimer**

These products are for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Though the lentiviral transduction particles produced are replication incompetent, it is recommended that they be treated as **Risk Group Level 2 (RGL-2)** organisms for laboratory handling.<sup>13</sup> Follow all published RGL-2 guidelines for laboratory handling and waste decontamination. Also, use extra caution when using lentiviral transduction particles that express shRNA-targeting genes involved in cell cycle control (such as tumor suppressor genes).

### Storage/Stability

All components are stable for at least 6 months after receipt when stored at  $-70^{\circ}\text{C}$ . We recommend aliquoting the material upon first thaw and avoiding repeated freeze/thaw cycles, which will severely impact titer.

### Preparation Instructions

1. Prepare mammalian cell cultures so that they are growing exponentially and are no more than 70–80% confluent before transduction.
2. Prepare a stock solution of hexadimethrine bromide (Polybrene) at 2 mg/mL in water.

### Procedure

The following protocol has been developed for screening in 96-well plates.

#### Day 1

- a. Add  $1.6 \times 10^4$  cells in fresh medium to the number of wells needed for each construct in a 96-well plate. Duplicate or triplicate wells for each lentiviral construct and control should be used.
- b. Incubate 18–20 hours at  $37^{\circ}\text{C}$  in a humidified incubator in an atmosphere of 5–7%  $\text{CO}_2$ .  
Note: The growth rates of cells vary greatly. Adjust the number of cells plated to accommodate a confluency of 70% upon transduction. Also account for the length of time the cells will be growing before downstream analysis when determining the plating density.

#### Day 2

- a. Remove medium from wells. To each well add 110  $\mu\text{L}$  of medium and hexadimethrine bromide to a final concentration of 8  $\mu\text{g/mL}$ . Gently swirl the plate to mix.  
Note: Hexadimethrine bromide enhances transduction of most cell types. Some cells, like primary neurons, are sensitive to hexadimethrine bromide. Do not add hexadimethrine bromide to these types of cells. If working with a cell type for the first time, a hexadimethrine control only well should be used to determine cell sensitivity.
- b. Add lentiviral particles at desired multiplicity of infection (MOI) to appropriate wells. Gently swirl the plate to mix. Incubate 18–20 hours at  $37^{\circ}\text{C}$  in a humidified incubator in an atmosphere of 5–7%  $\text{CO}_2$ . Cells may be incubated for as little as 4 hours before changing the medium containing lentiviral particles. Overnight incubation may be avoided when toxicity of the lentiviral particles is a concern.

Note: When transducing a lentiviral construct into a cell line for the first time, a range of volume or MOI should be tested. MOIs of 0.5, 1, 2, and 5 should be used to determine the optimal transduction efficiency and knockdown for each cell line. Transduction efficiency can be optimized using the MISSION TurboGFP Control Transduction Particles before assaying with shRNA constructs.

#### Multiplicity of Infection (MOI):

Multiplicity of Infection (MOI) is the number of transducing lentiviral particles per cell. It is highly recommended that for each new cell type to be transduced, a range of MOI be tested.

To calculate:

$$(\text{Total number of cells per well}) \times (\text{Desired MOI}) = \text{Total transducing units needed (TU)}$$

$$(\text{Total TU needed}) / (\text{TU/mL reported on C of A}) = \text{Total mL of lentiviral particles to add to each well}$$

#### Day 3

Remove the medium containing lentiviral particles from wells. Add fresh medium to a volume of 120  $\mu\text{L}$  to each well.

Note: For cell types that do not strongly adhere to the plate, 100  $\mu\text{L}$  of medium may be removed and replaced with 100  $\mu\text{L}$  of fresh medium.

#### Day 4

Perform one of the following based on whether the transduction experiment is transient or stable:

- a. For transient expression experiments - Harvest the cells and assay for interference of the target gene. This can be done by a variety of methods such as qRT-PCR or Western blot.
- b. For stable expression experiments - Remove the medium and replace it with fresh, complete medium that contains the appropriate amount of puromycin for selection of transduced cells. Proceed to Day 5.

Note: When the appropriate concentration of puromycin for a specific cell type is unknown, perform a titration, or Puromycin Kill Curve, in that cell line. Typically, puromycin concentrations ranging from 2–10  $\mu\text{g/mL}$  are sufficient to kill most untransduced mammalian cell lines.

### Incubation Time Post-Transduction

Incubation time depends on the cell line and the protein being expressed, as well as the vector construct. Non-transduced control cells under puromycin selection can be used to determine the post-transduction incubation time required to eliminate non-resistant cells for complete selection. Optimal puromycin concentration for selection should be determined by performing a titration, or Puromycin Kill Curve, in your cell line.

### Puromycin Kill Curve

Prior to beginning experiments, determine the concentration of puromycin for target cells by performing a Puromycin Kill Curve.

1. Plate  $1.6 \times 10^4$  cells into wells of a 96-well plate with 120  $\mu$ L of fresh medium.
2. The next day replace medium in the wells with medium containing varying concentrations of puromycin (0, 2, 4, 6, 8, 10  $\mu$ g/mL).
3. Examine viability of cells every 2 days.
4. Culture for 3–14 days depending on the growth rate of the cell type and the length of time that cells would typically be under selection during a normal experimental protocol. Replace the medium containing puromycin every 3 days. The minimum concentration of puromycin that causes complete cell death after the desired time should be used for that cell type and experiment.  
Note: Excess puromycin can cause many undesired phenotypic responses in most cell types.

### Day 5 and forward

Replace medium with fresh, puromycin-containing medium every 3–4 days until resistant colonies can be identified (generally, 10–12 days after selection). Pick a minimum of 5 puromycin-resistant colonies and expand each clone to assay for knockdown of the target gene.

Note: Due to the random integration of the lentivirus into the genome, varying levels of target gene knockdown may be seen from different puromycin-resistant clones. Testing a number of puromycin-resistant clones will allow a determination of which one provides the optimal degree of gene knockdown.

### Images

Cells that express fluorescent proteins should be imaged in a darkroom with a microscope capable of detecting fluorescence. Best images are acquired when corresponding channels are used with the microscope.

### **References**

1. Stewart, S.A. et al., Lentivirus-delivered stable gene silencing by RNAi in primary cells. *RNA*, **9**, 493-501 (2003).
2. Zufferey, R. et al., Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nat. Biotechnol.*, **15**, 871-85 (1997).
3. Zufferey, R. et al., Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. *J. Virol.*, **72**, 9873-80 (1998).
4. Burns, J.C. et al., Vesicular Stomatitis Virus G Glycoprotein Pseudotyped Retroviral Vectors: Concentration to a Very High Titer and Efficient Gene Transfer into Mammalian and Nonmammalian Cells. *Proc. Natl. Acad. Sci. USA*, **90**, 8033-8037 (1993).
5. Donello J.E. et al., Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. *J. Virol.*, **72**, 5085-92 (1998).
6. Zufferey, R. et al., Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. *J. Virol.*, **73**, 2886-92 (1999).
7. Whither RNAi? *Nature Cell Biology*, **5**, 489-490 (2003).
8. Furth, P.A. et al., The variability in activity of the universally expressed human cytomegalovirus immediate early gene 1 enhancer/promoter in transgenic mice. *Nucleic Acids Research*, **19**, 6205-6208 (1991).
9. Schorpp, M. et al., The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice. *Nucleic Acids Research*, **24**, 1787-1788 (1996).
10. Schardijn, G.H.C., and Statius Van Eps, L.W.,  $\beta_2$ -microglobulin: Its significance in the evaluation of renal function. *Kidney International*, **32**, 635-641 (1987).
11. Couchman, J.R. et al., RhoGDI: multiple functions in the regulation of Rho family GTPase activities. *Biochem. J.*, **390**, 1-9 (2005).
12. Meyer, A-K. et al., Defects in cytokinesis, actin reorganization and the contractile vacuole in cells deficient in RhoGDI. *EMBO*, **21**, 4539-4549 (2002).
13. NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) 2002 (<http://www4.od.nih.gov/oba>)

## Product Quick Reference Guide

| Catalog Number   | Vector Backbone | Insert  | Insert Sequence / Vector Description  |
|--|-----------------|---|---|
| Description  |                 |   |   |
| <b>SHC001V</b><br><b>SHC001H</b>                               | TRC1/1.5        | No hairpin  | No shRNA Insert   |
| MISSION pLKO.1-puro<br>Empty Vector Control                    |                 |   |   |
| <b>SHC201V</b>   | TRC2            | No hairpin  | No shRNA Insert   |
| MISSION TRC2 pLKO.5-<br>puro Empty Vector<br>Control           |                 |   |   |
| <b>SHC002V</b><br><b>SHC002H</b>                               | TRC1/1.5        | Non human or<br>mouse shRNA                               | CCGGCAACAAGATGAAGAGCACCAACTC-<br>GAGTTGGTGCTCTTCATCTTGTTGTTTT   |
| MISSION pLKO.1-puro<br>Non-Mammalian shRNA<br>Control          |                 |   |   |
| <b>SHC202V</b>   | TRC2            | Non human or<br>mouse shRNA                               | CCGGCAACAAGATGAAGAGCACCAACTC-<br>GAGTTGGTGCTCTTCATCTTGTTGTTTT   |
| MISSION TRC2 pLKO.5-<br>puro Non-Mammalian<br>shRNA Control    |                 |   |   |
| <b>SHC003V</b><br><b>SHC003H</b>                               | TRC1/1.5        | No hairpin  | No shRNA insert.<br>Contains TurboGFP gene, under the control of the CMV promoter.<br>TurboGFP is an improved variant of the green fluorescent protein<br>copGFP cloned from the copepoda <i>Pontellina plumata</i> . |
| MISSION pLKO.1-puro-<br>CMV-TurboGFP™<br>Positive Control      |                 |   |   |
| <b>SHC203V</b>   | TRC2            | No hairpin  | No shRNA insert.<br>Contains TurboGFP gene, under the control of the CMV promoter.<br>TurboGFP is an improved variant of the green fluorescent protein<br>copGFP cloned from the copepoda <i>Pontellina plumata</i> . |
| MISSION TRC2 pLKO.5-<br>puro-CMV-TurboGFP™<br>Positive Control |                 |   |   |
| <b>SHC004V</b>   | TRC1/1.5        | shRNA<br>targeting<br>TurboGFP                            | CCGGCGTGATCTTCACCGACAAGATCTC-<br>GAGATCTTGTCGGTGAAGATCACGTTTT   |
| MISSION pLKO.1-puro<br>TurboGFP™ shRNA<br>Control              |                 |   |   |
| <b>SHC204V</b>   | TRC2            | shRNA<br>targeting<br>TurboGFP                            | CCGGCGTGATCTTCACCGACAAGATCTC-<br>GAGATCTTGTCGGTGAAGATCACGTTTT   |
| MISSION TRC2 pLKO.5-<br>puro TurboGFP™<br>shRNA Control        |                 |   |   |
| <b>SHC005V</b>   | TRC1/1.5        | shRNA<br>targeting eGFP                                   | CCGGTACAACAGCCACAACGTCTATCTC-<br>GAGATAGACGTTGTGGCTGTTGATTTTT   |
| MISSION pLKO.1-puro<br>eGFP shRNA Control                      |                 |   |   |
| <b>SHC007V</b>   | TRC1/1.5        | shRNA<br>targeting<br>Luciferase                          | CCGGCGCTGAGTACTTCGAAATGTCCTC-<br>GAGGACATTTCAAGTACTCAGCGTTTT  |
| MISSION pLKO.1-puro<br>Luciferase shRNA<br>Control             |                 |   |   |
| <b>SHC008V</b>   | TRC1/1.5        | shRNA<br>targeting human<br>β <sub>2</sub> -microglobulin | CCGGCAGCAGAGAATGGAAAGTCAACTC-<br>GAGTTGACTTTCCATTCTCTGCTGTTTT   |
| MISSION pLKO.1-puro<br>B2M shRNA Control                       |                 |   |   |
| <b>SHC009V</b>   | TRC1/1.5        | shRNA<br>targeting human<br>ARHGDI                        | CCGGCAAGATTGACAAGACTGACTACTC-<br>GAGTAGTCAGTCTTGTAATCTTGTTTT  |
| MISSION pLKO.1-puro<br>ARHGDI shRNA<br>Control                 |                 |   |   |
| <b>SHC010V</b>   | TRC1/1.5        | No hairpin  | No shRNA insert.<br>Contains TagCFP gene under the control of the CMV promoter.   |
| MISSION pLKO.1-puro-<br>CMV-TagCFP™ Positive<br>Control        |                 |   |   |
| <b>SHC011V</b>   | TRC1/1.5        | No hairpin  | No shRNA insert.<br>Contains TagYFP gene under the control of the CMV promoter.   |
| MISSION pLKO.1-puro-<br>CMV-TagYFP™ Positive<br>Control        |                 |   |   |

**Product Quick Reference Guide (continued)**

| <b>Catalog Number</b>   | <b>Vector Backbone</b> | <b>Insert</b>              | <b>Insert Sequence / Vector Description</b>                                       |
|---|------------------------|----------------------------|---|
| <b>SHC012V</b>  | TRC1/1.5               | No hairpin                 | No shRNA insert.<br>Contains TagRFP gene under the control of the CMV promoter.   |
| MISSION pLKO.1-puro-CMV-TagRFP™ Positive Control                    |                        |                            |   |
| <b>SHC013V</b>  | TRC1/1.5               | No hairpin                 | No shRNA insert.<br>Contains FP635 gene under the control of the CMV promoter.    |
| MISSION pLKO.1-puro-CMV-TagFP635™ Positive Control                  |                        |                            |   |
| <b>SHC014V</b>  | TRC1/1.5               | No hairpin                 | No shRNA insert.<br>Contains TurboGFP gene under the control of the UbC promoter. |
| MISSION pLKO.1-puro-UbC-TurboGFP™ Positive Control                  |                        |                            |   |
| <b>SHC015V</b>  | TRC1/1.5               | No hairpin                 | No shRNA insert.<br>Contains FP635 gene under the control of the UbC promoter.    |
| MISSION pLKO.1-puro-UbC-TagFP635™ Positive Control                  |                        |                            |   |
| <b>SHC016V</b><br><b>SHC016H</b>                                    | TRC1/1.5               | Non-target shRNA           | CCGGGCGCGATAGCGCTAATAATTTCTC-GAGAAATTATTAGCGCTATCGCGCTTTTT                        |
| MISSION pLKO.1-puro Non-Target shRNA Control                        |                        |                            |   |
| <b>SHC216V</b><br>MISSION TRC2 pLKO.5-puro Non-Target shRNA Control | TRC2                   | Non-target shRNA           | CCGGGCGCGATAGCGCTAATAATTTCTC-GAGAAATTATTAGCGCTATCGCGCTTTTT                        |
| <b>SHC312V</b>  | IPTG Inducible         | Non-target shRNA           | CCGGGCGCGATAGCGCTAATAATTTCTC-GAGAAATTATTAGCGCTATCGCGCTTTTT                        |
| MISSION 1X LacO Inducible Non-Target shRNA Control                  |                        |                            |   |
| <b>SHC332V</b>  | IPTG Inducible         | Non-target shRNA           | CCGGGCGCGATAGCGCTAATAATTTCTC-GAGAAATTATTAGCGCTATCGCGCTTTTT                        |
| MISSION 3X LacO Inducible Non-Target shRNA Control                  |                        |                            |   |
| <b>SHC314V</b>  | IPTG Inducible         | shRNA targeting TurboGFP   | CCGGCGTGATCTTCACCGACAAGATCTC-GAGATCTTGTCGGTGAAGATCACGTTTTT                        |
| MISSION 1X LacO Inducible TurboGFP™ shRNA Control                   |                        |                            |   |
| <b>SHC334V</b>  | IPTG Inducible         | shRNA targeting TurboGFP   | CCGGCGTGATCTTCACCGACAAGATCTC-GAGATCTTGTCGGTGAAGATCACGTTTTT                        |
| MISSION 3X LacO Inducible TurboGFP™ shRNA Control                   |                        |                            |   |
| <b>SHC317V</b>  | IPTG Inducible         | shRNA targeting Luciferase | CCGGCGCTGAGTACTTCGAAATGTCCTC-GAGGACATTTTGAAGTACTCAGCGTTTTT                        |
| MISSION 1X LacO Inducible Luciferase shRNA Control                  |                        |                            |   |
| <b>SHC337V</b>  | IPTG Inducible         | shRNA targeting Luciferase | CCGGCGCTGAGTACTTCGAAATGTCCTC-GAGGACATTTTGAAGTACTCAGCGTTTTT                        |
| MISSION 3X LacO Inducible Luciferase shRNA Control                  |                        |                            |   |

**Control Selection Table**

| Recommended Control  | Objective   |
|--|---|
| Negative Control: Untreated Cells  | Untreated cells will provide a reference point for comparing all other samples.   |
| Negative Control: Transduction with empty viral particles, containing no shRNA insert  | <p>MISSION pLKO.1-puro Empty Vector Control Transduction Particles, Catalog Nos. SHC001V, SHC001H.</p> <p>MISSION TRC2 pLKO.5-puro Empty Vector Control Transduction Particles, Catalog No. SHC201V.</p> <p>MISSION pLKO.1-puro-CMV-TurboGFP™ Positive Control Transduction Particles, Catalog Nos. SHC003V, SHC003H.</p> <p>MISSION TRC2 pLKO.5-puro-CMV-TurboGFP™ Positive Control, Catalog No. SHC203V.</p> <p>MISSION pLKO.1-puro-CMV-TagCFP™ Positive Control, Catalog No. SHC010V.</p> <p>MISSION pLKO.1-puro-CMV-TagYFP™ Positive Control, Catalog No. SHC011V.</p> <p>MISSION pLKO.1-puro-CMV-TagRFP™ Positive Control, Catalog No. SHC012V.</p> <p>MISSION pLKO.1-puro-CMV-TagFP635™ Positive Control, Catalog No. SHC013V.</p> <p>MISSION pLKO.1-puro-UbC-TurboGFP™ Positive Control, Catalog No. SHC014V.</p> <p>MISSION pLKO.1-puro-UbC-TagFP635™ Positive Control, Catalog No. SHC015V.</p> <p>These empty viral particles can serve as useful negative controls that will not activate the RNAi pathway because they do not contain an shRNA insert. It will allow for the observation of cellular effects of the transduction process. Cells transduced with the empty viral particles will provide a useful reference point for comparing specific knockdown.</p>   |
| Negative Control: Transduction with non-targeting shRNA                                | <p>MISSION pLKO.1-puro Non-Mammalian shRNA Control Transduction Particles, Catalog Nos. SHC002V and SHC002H.</p> <p>MISSION TRC2 pLKO.5-puro Non-Mammalian shRNA Control Transduction Particles, Catalog No. SHC202V.</p> <p>MISSION pLKO.1-puro Non-Target shRNA Control Transduction Particles, Catalog Nos. SHC016V and SHC016H.</p> <p>MISSION TRC2 pLKO.5-puro Non-Target shRNA Control Transduction Particles, Catalog No. SHC216V.</p> <p>MISSION 1X LacO Inducible Non-Target shRNA Control Transduction Particles, Catalog No. SHC312V.</p> <p>MISSION 3X LacO Inducible Non-Target shRNA Control Transduction Particles, Catalog No. SHC332V.</p> <p>The Non-Target shRNA transduction particles are produced from the sequence-verified lentiviral plasmid vectors containing non-targeting shRNAs. These non-targeting shRNAs are useful negative controls that will activate RISC and the RNAi pathway, but do not target any human or mouse genes. This allows for examination of the effects of shRNA transduction on gene expression. Cells infected with the non-target shRNA will also provide a useful reference for interpretation of knockdown.</p>  |
| Positive Control for transduction: Transduction with positive reporter viral particles | <p>MISSION Control Transduction Particles, Catalog Nos. SHC003V, SHC003H, SHC010V, SHC011V, SHC012V, SHC013V, SHC014V, and SHC015V.</p> <p>MISSION TRC2-pLKO-puro CMV-TurboGFP, Catalog No. SHC203V.</p> <p>These are useful positive controls for measuring transduction efficiency and optimizing shRNA delivery.</p>   |
| Positive Controls for knockdown: Transduction with shRNA targeting report gene         | <p>MISSION TurboGFP shRNA Control Transduction Particles, Catalog Nos. SHC004V, SHC004H.</p> <p>MISSION TRC2-pLKO-puro TurboGFP shRNA Control Transduction Particles, Catalog No. SHC204V.</p> <p>MISSION 1X LacO Inducible TurboGFP™ shRNA Control Transduction Particles, Catalog No. SHC314V.</p> <p>MISSION 3X LacO Inducible TurboGFP™ shRNA Control Transduction Particles, Catalog No. SHC334V.</p> <p>The TurboGFP shRNA transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-puro vector containing shRNA that targets TurboGFP (Catalog No. SHC004). These particles can be used as a positive control to quickly visualize knockdown. This TurboGFP shRNA has been experimentally shown to reduce GFP expression by 99.6% in HEK293T cells after 24 hours. Because this shRNA targets TurboGFP, and it does not target any human or mouse genes, it can also be used as a negative non-target control in shRNA experiments.</p> <p>MISSION eGFP shRNA Control Transduction Particles, Catalog Number SHC005V</p> <p>The eGFP shRNA transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-puro vector containing shRNA that targets eGFP (Catalog No. SHC005), and can be used as a positive control to quickly visualize knockdown. These eGFP (GenBank Accession No. pEGFP U55761) shRNA transduction particles are also useful as a negative non-target control because the shRNA does not target any human or mouse genes.</p> |



**Control Selection Table (continued)**


| Recommended Control   | Objective   |
|---|---|
| Positive Controls for knockdown:<br>Transduction with shRNA targeting report gene (continued) | MISSION Luciferase shRNA Control Transduction Particles, Catalog No. SHC007V.<br>MISSION 1X LacO Inducible Luciferase shRNA Control Transduction Particles, Catalog No. SHC317V.<br>MISSION 3X LacO Inducible Luciferase shRNA Control Transduction Particles, Catalog No. SHC337V.   |
|   | The MISSION Luciferase shRNA transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-puro vector containing an shRNA insert that targets luciferase (Catalog Number SHC007) from North American Firefly, <i>Photinus pyralis</i> (GenBank Accession No. M15077). These transduction particles can be used as a positive control to quickly confirm knockdown. Because the shRNA targets firefly luciferase, and it does not target any human or mouse genes, it can also be used as a negative non-target control in shRNA experiments. |
| Positive Controls for knockdown:<br>Transduction with shRNA targeting gene                    | MISSION shRNA Human Positive Control Vector #1 Transduction Particles, Catalog No. SHC008V.   |
|   | The $\beta_2$ -microglobulin shRNA transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-Puro vector containing shRNA that targets human $\beta_2$ -microglobulin (Catalog No. SHC008). This control will provide clear and measurable knockdown of the human target, typically 80–90% in A549 cells, a human epithelial lung carcinoma cell line.  |
|   | MISSION shRNA Human Positive Control Vector #2 Transduction Particles, Cat. No. SHC009V.  |
|   | The ARHGDI $\alpha$ shRNA transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-Puro vector containing shRNA that targets human Rho GDP Dissociation Inhibitor $\alpha$ (Catalog No. SHC009). This control will provide clear and measurable knockdown of the human target, typically 80–90% in A549 cells, a human epithelial lung carcinoma cell line.  |

**Troubleshooting Guide**

| Problem  | Possible Cause  | Suggested Solutions  |
|--|---|--|
| Low level of target gene knockdown due to low transduction efficiency. | Hexadimethrine bromide not included during transduction.      | Transduce in the presence of hexadimethrine bromide.   |
|  | Non-dividing cell type used.                                  | Transduce at a higher MOI.   |
|  | MOI is too low.   | Transduce at a higher MOI.   |
|  | Cells were harvested and assayed too soon after transduction. | The shRNA must be permitted to accumulate in cells. Harvest 48–72 hours after transduction.  |
| No gene knockdown is observed.   | Viral stock stored incorrectly.                               | Store stocks at $-70^{\circ}\text{C}$ . Do not freeze/thaw more than 3 times.  |
|  | MOI is too low.   | Transduce at a higher MOI.   |
| Cytotoxic effects observed after transduction.                         | Hexadimethrine bromide was used during transduction.          | Be sure that cells are not sensitive to hexadimethrine bromide. Omit the hexadimethrine bromide during the transduction.   |
| No fluorescent protein detected  | Cells need more time to express the fluorescent protein       | Protein expression times are cell line dependent; continue viewing fluorescence daily with media changes as needed. Approximately 6 days may be needed to view protein expression.                             |
|  | Cells need to be imaged in a darkroom                         | Cells that express fluorescent proteins should be imaged in a darkroom with a microscope capable of detecting fluorescence. Best images are acquired when corresponding channels are used with the microscope. |


### Figure 1. TRC1 and TRC1.5 Lentiviral Plasmid Vector pLKO.1-puro Features

| Name       | Description  |
|------------|--|
| U6         | U6 Promoter  |
| cppt       | Central polypurine tract                           |
| hPGK       | Human phosphoglycerate kinase eukaryotic promoter  |
| puroR      | Puromycin resistance gene for mammalian selection  |
| SIN/3' LTR | 3' self inactivating long terminal repeat          |
| f1 ori     | f1 origin of replication                           |
| ampR       | Ampicillin resistance gene for bacterial selection |
| pUC ori    | pUC origin of replication                          |
| 5' LTR     | 5' long terminal repeat                            |
| Psi        | RNA packaging signal                               |
| RRE        | Rev response element                               |




**Figure 2. TRC2 Lentiviral Plasmid Vector  
TRC2-pLKO-puro Features**

| Name       | Description   |
|------------|---|
| U6         | U6 Promoter   |
| cppt       | Central polypurine tract                                    |
| hPGK       | Human phosphoglycerate kinase eukaryotic promoter           |
| puroR      | Puromycin resistance gene for mammalian selection           |
| WPRE       | Woodchuck Hepatitis Post-Transcriptional Regulatory Element |
| SIN/3' LTR | 3' self inactivating long terminal repeat                   |
| f1 ori     | f1 origin of replication                                    |
| ampR       | Ampicillin resistance gene for bacterial selection          |
| pUC ori    | pUC origin of replication                                   |
| 5' LTR     | 5' long terminal repeat                                     |
| Psi        | RNA packaging signal  |
| RRE        | Rev response element  |




**Figure 3.**  
**Inducible shRNA Vectors**



**Figure 4.**  
**Excitation and Emission Wavelengths for Fluorescent Proteins**

| Catalog Number | Fluorophore | Excitation (nm) | Emission (nm) |
|----------------|-------------|-----------------|---------------|
| SHC003/SHC014  | TurboGFP    | 482             | 502           |
| SHC010         | TagCFP      | 458             | 480           |
| SHC011         | TagYFP      | 508             | 524           |
| SHC012         | TagRFP      | 555             | 584           |
| SHC013/SHC015  | TagFP635    | 588             | 635           |



**Label Licenses:****These licenses are relevant for all MISSION products:**

Use of this product for Commercial Purposes requires a license from Sigma-Aldrich Corporation. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party, or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration, but excludes not-for-profit core facilities providing services within their own research institutions at cost. Core facilities are invited to join Sigma-Aldrich's RNAi Partnership Program. Details of Sigma-Aldrich's RNAi Partnership Program can be found at [www.sigma.com/rpp](http://www.sigma.com/rpp).

This product is licensed under U.S. Pat. Nos. 5,817,491; 5,591,624; 5,716,832; 6,312,682; 6,669,936; 6,235,522; 6,924,123 and foreign equivalents from Oxford BioMedica (UK) Ltd., Oxford, UK, and is provided for use in academic and commercial *in vitro* and *in vivo* research for elucidating gene function, and for validating potential gene products and pathways for drug discovery and development, but excludes any use of LentiVector® technology for: creating transgenic birds for the purpose of producing useful or valuable proteins in the eggs of such transgenic birds, the delivery of gene therapies, and for commercial production of therapeutic, diagnostic or other commercial products not intended for research use where such products do not consist of or incorporate a lentiviral vector. Information about licenses for commercial uses excluded under this license is available from Oxford BioMedica (UK), Ltd., Medawar Center, Oxford Science Park, Oxford OX4 4GA UK [enquiries@oxfordbiomedica.co.uk](mailto:enquiries@oxfordbiomedica.co.uk) or BioMedica Inc., 11622 El Camino Real #100, San Diego CA 92130-2049 USA. LentiVector is a registered US and European Community trademark of Oxford BioMedica plc.

This product (based upon the lentikat system) is sub-licensed from Invitrogen Corporation under U.S. Patent Nos. 5,686,279, 5,834,256, 5,858,740; 5,994,136; 6,013,516; 6,051,427, 6,165,782, and 6,218,187 and corresponding patents and applications in other countries for internal research purposes only. Use of this technology for gene therapy applications or bioprocessing other than for nonhuman research use requires a license from Cell Genesys, Inc. Please contact Cell Genesys, Inc. at 342 Lakeside Drive, Foster City, California 94404. Use of this technology to make or sell products or offer services for consideration in the research market requires a license from Invitrogen Corporation, 1600 Faraday Ave., Carlsbad, CA 92008.

**These licenses are relevant for all MISSION products but SHP001:**

This product is for non-clinical research use only. It is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic, therapeutic or high throughput drug discovery purposes (the screening of more than 10,000 compounds per day) is prohibited. This product is sold under license from Invitrogen Corporation. In order to obtain a license to use this product for these commercial purposes, contact The Regents of the University of California. This product or the use of this product is covered by U.S. Patent No. 5,624,803 owned by The Regents of the University of California.

**These licenses are relevant for all MISSION products but SHC001, SHC001V, SHC001H, SHC003, SHC003V, SHC003H, SHP001:**

Licensed under Carnegie Institution US Patent 6,506,559 and Massachusetts Institute of Technology and for laboratory and commercial research use only.

This product is licensed under agreement with Benitec Australia Ltd. and CSIRO as co-owners of U.S. Pat. No. 6,573,099 and foreign counterparts, for use in research to understand, diagnose, monitor, treat and prevent human diseases and disorders, including the use of animals for such research use, except that use of ddRNAi as a therapeutic agent or as a method of disease treatment, prevention, diagnosis or for disease monitoring is excluded. Information regarding licenses to these patents for use of ddRNAi as a therapeutic agent or for other uses excluded under this license is available from Benitec at [licensing@benitec.com](mailto:licensing@benitec.com). Information about licenses for the use of ddRNAi in other fields, is available from CSIRO at [pi.csiro.au/RNAi](http://pi.csiro.au/RNAi).

**This license is relevant for all MISSION products but SHC002, SHC002V, SHC002H, SHC003, SHC003V, SHC003H, SHC004, SHC004V, SHC004H, SHC010, SHC010V, SHC011, SHC011V, SHC012, SHC012V, SHC013, SHC013V, SHC014, SHC014V, SHC015, SHC015V, SHP001:**

The MISSION shRNA Library of The RNAi Consortium is produced and distributed under license from the Massachusetts Institute of Technology.

**This license is relevant for MISSION products SHC003, SHC003V, SHC003H, SHC010, SHC010V, SHC011, SHC011V, SHC012, SHC012V, SHC013, SHC013V, SHC014, SHC014V, SHC015, SHC015V, SHXC01:**

This product contains a proprietary nucleic acid coding for a proprietary fluorescent protein(s) intended to be used for research purposes only. Any use of the proprietary nucleic acid or fluorescent proteins coding by proprietary nucleic acids other than for research use is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at [license@evrogen.com](mailto:license@evrogen.com).

**This license is relevant for MISSION products containing the WPRE, including SHC201, SHC201V, SHC202, SHC202V, SHC203, SHC203V, SHC204, SHC204V:**

All Mission TRC II Lentiviral backbone-containing products contain a specific genetic component (WPRE), which is licensed from the Salk Institute for Biological Studies and covered under the following patents:

U.S. Patent No. 6,136,597, U.S. Patent No. 6,284,469, U.S. Patent No. 6,312,912, U.S. Patent No. 6,287,814.

**Purchaser Notification:**

Licensee has a license to sell the Product containing WPRE, under the terms described below. Any use of WPRE outside of Licensee's Product or the Product's intended use, requires a license as detailed below. Before using the Product containing WPRE, please read the following license agreement. If you do not agree to be bound by its terms, contact Licensee within 10 days for authorization to return the unused Product containing WPRE and to receive a full credit.

Licensee grants you a non-exclusive license to use the enclosed Product containing WPRE in its entirety for its intended research use. The Product containing WPRE is being transferred to you in furtherance of, and reliance on, such license. Any use of WPRE outside of Licensee's Product or the Product's intended use including for Commercial Purposes, requires a license from the Salk Institute for Biological Studies. Commercial Purposes means any activity by a party for consideration, but excludes not-for-profit core facilities providing services within their own research institutions at cost. This license agreement is effective until terminated. You may terminate it at any time by destroying all Products containing WPRE in your control. It will also terminate automatically if you fail to comply with the terms and conditions of the license agreement. You shall, upon termination of the license agreement, destroy all Products containing WPRE in your control, and so notify Licensee in writing.

This License shall be governed in its interpretation and enforcement by the laws of the State of California.

**Contact for WPRE Licensing:**

The Salk Institute for Biological Studies  
10010 North Torrey Pines Road  
La Jolla, CA 92037  
Attn.: Office of Technology Management  
Phone: (858) 453-4100 extension 1703  
Fax: (858) 546-8093

This Product is covered by US and foreign patent applications or patents and other proprietary intellectual property rights owned by CSHL ("CSHL shRNA IP Rights"), including U.S. Patent Nos. 8,153,776, 8,202,846, 8,383,599, 8,829,264, and EP1546174.

Subject to acceptance and all terms and conditions of this License, sale of the Product to Buyer by Sigma-Aldrich, Co. (acting under its license, an "Authorized Sale") conveys to Buyer only the nonexclusive, nontransferable right (with no right to sublicense) under the shRNA IP Rights to use the Product solely for Customer's internal research purposes, and only at its facility where the Product is delivered by Sigma-Aldrich, Co.

The Product is for research use only and may not be used *in vitro* or *in vivo* for any diagnostic, preventative, therapeutic or vaccine application, or used (directly or indirectly) in humans for any purpose.

**Non-Profit Buyers.** If Buyer is a Non-Profit Entity, then the following additional restrictions will apply:

Customer obtains no right to use, develop or otherwise exploit the product for any commercial purpose.

**Commercial Buyers.** If Buyer is a Commercial Entity, then the following additional restrictions will apply:

A Product sale is an Authorized Sale only if Buyer has already entered into a separate written agreement that has been executed by CSHL or Hairpin Technologies, that covers the CSHL shRNA IP Rights, and that is then currently in effect. Any delivery or transfer of Product to Customer outside of an Authorized Sale is void, conveys no implied or express right under this license and Customer will immediately return Product to Sigma-Aldrich for a refund.

"Commercial Entity" means any entity or organization other than a Non-Profit Entity.

"CSHL" means Cold Spring Harbor Laboratory.

"Hairpin Technologies" means Hairpin Technologies, Inc. located at 2200 Smithtown Avenue, Ronkonkoma, NY 11779, [www.hairpintechnologies.com](http://www.hairpintechnologies.com).

"Non-Profit Entity" means any college, university or governmental entity (including without limitation, governmental and quasi-governmental institutes and research laboratories), or any non-profit scientific, research or educational organization of the type described in section 501(c)(3) of the Internal Revenue Code or qualified under a state non-profit organization statute.

"Product" means a product (including, without limitation, expression vectors encoding a shRNA, the design, manufacture or use of which (in whole or in part) is the subject of the shRNA IP Rights, and is deemed to include all components, progeny, reproductions, modified versions and other derivatives thereof.

This license is subject to a license from CSHL or Hairpin Technologies, and CSHL and Hairpin Technologies reserves all other rights under its license. For information on licensing rights for Commercial Entities, including use of this product for purposes other than research and trial licenses, please contact Hairpin Technologies, Inc. at [info@hairpintechnologies.com](mailto:info@hairpintechnologies.com) or call (631) 881-0844.

MISSION is a registered trademark of Sigma-Aldrich Co. LLC.

TurboGFP, TagCFP, TagYFP, TagRFP, and TagFP635 are trademarks of Evrogen Co.

KET,TD,RC,DP,PHC,MAM 08/17-1